BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29035458)

  • 1. Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.
    Ahlborn LB; Madsen M; Jonson L; Nielsen FC; Lassen U; Yde CW; Mau-Sorensen M
    Clin Lab; 2017 Oct; 63(10):1755-1759. PubMed ID: 29035458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
    Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
    Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative analysis of circulating tumor DNA stability In K
    Kang Q; Henry NL; Paoletti C; Jiang H; Vats P; Chinnaiyan AM; Hayes DF; Merajver SD; Rae JM; Tewari M
    Clin Biochem; 2016 Dec; 49(18):1354-1360. PubMed ID: 27129799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
    Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
    PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy - Performance of the PAXgene® Blood ccfDNA Tubes for the isolation and characterization of cell-free plasma DNA from tumor patients.
    Schmidt B; Reinicke D; Reindl I; Bork I; Wollschläger B; Lambrecht N; Fleischhacker M
    Clin Chim Acta; 2017 Jun; 469():94-98. PubMed ID: 28373054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients.
    Risberg B; Tsui DWY; Biggs H; Ruiz-Valdepenas Martin de Almagro A; Dawson SJ; Hodgkin C; Jones L; Parkinson C; Piskorz A; Marass F; Chandrananda D; Moore E; Morris J; Plagnol V; Rosenfeld N; Caldas C; Brenton JD; Gale D
    J Mol Diagn; 2018 Nov; 20(6):883-892. PubMed ID: 30165204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing.
    Alidousty C; Brandes D; Heydt C; Wagener S; Wittersheim M; Schäfer SC; Holz B; Merkelbach-Bruse S; Büttner R; Fassunke J; Schultheis AM
    J Mol Diagn; 2017 Sep; 19(5):801-804. PubMed ID: 28732213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.
    van Dessel LF; Beije N; Helmijr JC; Vitale SR; Kraan J; Look MP; de Wit R; Sleijfer S; Jansen MP; Martens JW; Lolkema MP
    Mol Oncol; 2017 Mar; 11(3):295-304. PubMed ID: 28164427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
    Sherwood JL; Corcoran C; Brown H; Sharpe AD; Musilova M; Kohlmann A
    PLoS One; 2016; 11(2):e0150197. PubMed ID: 26918901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma.
    Warton K; Yuwono NL; Cowley MJ; McCabe MJ; So A; Ford CE
    Mol Diagn Ther; 2017 Oct; 21(5):563-570. PubMed ID: 28631163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.
    Toro PV; Erlanger B; Beaver JA; Cochran RL; VanDenBerg DA; Yakim E; Cravero K; Chu D; Zabransky DJ; Wong HY; Croessmann S; Parsons H; Hurley PJ; Lauring J; Park BH
    Clin Biochem; 2015 Oct; 48(15):993-8. PubMed ID: 26234639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
    Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing.
    Wong D; Moturi S; Angkachatchai V; Mueller R; DeSantis G; van den Boom D; Ehrich M
    Clin Biochem; 2013 Aug; 46(12):1099-1104. PubMed ID: 23643886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of ImproGene cfDNA blood collection tubes for mutation analysis in cancer patients.
    Zhang S; Zhou D; Li S; Bai Y; Huang B; Han J; Xu M; Wang S; Deng G
    Scand J Clin Lab Invest; 2022 Sep; 82(5):378-384. PubMed ID: 35861435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
    Merker JD; Oxnard GR; Compton C; Diehn M; Hurley P; Lazar AJ; Lindeman N; Lockwood CM; Rai AJ; Schilsky RL; Tsimberidou AM; Vasalos P; Billman BL; Oliver TK; Bruinooge SS; Hayes DF; Turner NC
    J Clin Oncol; 2018 Jun; 36(16):1631-1641. PubMed ID: 29504847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
    Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
    Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.